Nordea Investment Management AB Purchases 25,987 Shares of Solventum Corporation $SOLV

Nordea Investment Management AB grew its position in Solventum Corporation (NYSE:SOLV) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 758,847 shares of the company’s stock after acquiring an additional 25,987 shares during the period. Nordea Investment Management AB’s holdings in Solventum were worth $54,880,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of SOLV. United Services Automobile Association acquired a new stake in Solventum during the 1st quarter valued at $239,000. Woodline Partners LP increased its stake in shares of Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after buying an additional 3,377 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after buying an additional 10,425 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in Solventum by 49.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,301 shares of the company’s stock worth $99,000 after buying an additional 428 shares in the last quarter. Finally, Strs Ohio bought a new stake in Solventum during the 1st quarter worth about $1,431,000.

Solventum Price Performance

Shares of SOLV opened at $80.00 on Thursday. The stock has a market cap of $13.88 billion, a P/E ratio of 9.22, a price-to-earnings-growth ratio of 7.96 and a beta of 0.34. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $88.20. The stock’s 50-day moving average price is $80.65 and its two-hundred day moving average price is $75.58. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the prior year, the business posted $1.64 EPS. Solventum’s revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, equities analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum declared that its board has authorized a stock buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 7.5% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts have weighed in on SOLV shares. UBS Group restated a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Zacks Research downgraded Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Piper Sandler restated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Stifel Nicolaus raised their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Five investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $88.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.